Trial · NCT01999517
Contrast Nephropathy and Nitrates
NCT01999517, Phase 4, Completed, Mt. Sinai Medical Center, Miami; results first posted 2019-10-29
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Contrast Nephropathy and Nitrates. Trials, record NCT01999517. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01999517
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Contrast Nephropathy and Nitrates
- NCT number
- NCT01999517
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 122 participants, actual
- Lead sponsor
- Mt. Sinai Medical Center, Miami
- Conditions
- Contrast Induced Nephropathy
- Interventions
- Intravenous Nitroglycerin, IV Fluids
- First posted
- 2013-12-03
- Last updated
- 2019-10-29
- Results first posted
- 2019-10-29
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in GFR | Baseline and 48 to 72 hours post-PCI | The primary endpoint for this trial will be to determine the change in glomerular filtration rate after exposure to contrast media. We will compare the change in GFR before and after PCI of the group that received intravenous nitroglycerin with the change in GFR before and after PCI of the group that did not receive intravenous nitroglycerin. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in GFR | Baseline and 48 to 72 hours post-PCI | mL/min | MEDIAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in GFR | Intravenous Nitroglycerin | 1.8 | Inter-Quartile Range -5.9 to 6.9 | mL/min | |
| Change in GFR | Placebo | -4.1 | Inter-Quartile Range -9.3 to 3 | mL/min |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Intravenous Nitroglycerin | 68 | |
| Overall Study | STARTED | Placebo | 54 | |
| Overall Study | COMPLETED | Intravenous Nitroglycerin | 68 | |
| Overall Study | COMPLETED | Placebo | 54 | |
| Overall Study | NOT COMPLETED | Intravenous Nitroglycerin | 0 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hypotension | Cardiac disorders | Intravenous Nitroglycerin | 4 | 68 | 4 |
| other | Hypotension | Cardiac disorders | Placebo | 2 | 54 | 2 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Intravenous Nitroglycerin | 0 | 68 |
| Total, all-cause mortality | Placebo | 0 | 54 |
| Total, other adverse events | Intravenous Nitroglycerin | 4 | 68 |
| Total, other adverse events | Placebo | 2 | 54 |
| Total, serious adverse events | Intravenous Nitroglycerin | 0 | 68 |
| Total, serious adverse events | Placebo | 0 | 54 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Intravenous Nitroglycerin vs Placebo: deaths from any cause | Trial comparisons |
| Intravenous Nitroglycerin vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01999517
GET https://conductscience.org/api/trials/v1/NCT01999517/registered